CoChat

T-Cell Transfer Therapy Targeting Mutant KRAS

Open access
· 2017 · New England Journal of Medicine
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

To the Editor: Tran et al. (Dec. 8 issue)1 describe a remarkable case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRAS G12D and restricted to the major histocompatibility complex class I allele HLA-C*08:02. The authors hypothesize that in the United States alone, thousands of patients per year may be eligible for T-cell–based immunotherapy targeting KRAS G12D. To estimate how common this opportunity may be, we identified 151 patients with KRAS G12D mutations out of 6125 patients in the Cancer Genome Atlas. Of these, only 4 had the HLA-C*08:02 allele as determined by a validated computational method.2,3 We then investigated immune activity in tumor samples using established gene signatures.4,5 Comparing KRAS G12D–positive tumors with disease-matched KRAS wild-type tumors, we found no evidence of unique immune activity. Nor did we find evidence of unique immune activity in patients with the HLA-C*08:02 allele, regardless of KRAS mutation status. Immunotherapy targeting KRAS G12D in patients with the HLA-C*08:02 allele appears to be an important but rare opportunity. Evaluation of other KRAS mutations and alleles is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1616637

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Venue
New England Journal of Medicine
Published
2017-02-16
Volume
376
Issue
7
Pages
e11
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2975987657
Cited by
42
References
2
FWCI
2.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.